463 related articles for article (PubMed ID: 26456955)
1. A comparison of four antiepileptic drugs in status epilepticus: experience from India.
Misra UK; Kalita J
Int J Neurosci; 2016 Nov; 126(11):1013-9. PubMed ID: 26456955
[TBL] [Abstract][Full Text] [Related]
2. Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus.
Brigo F; Bragazzi N; Nardone R; Trinka E
Epilepsy Behav; 2016 Nov; 64(Pt A):110-115. PubMed ID: 27736657
[TBL] [Abstract][Full Text] [Related]
3. Management of generalised convulsive status epilepticus (SE): A prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam--Pilot study.
Mundlamuri RC; Sinha S; Subbakrishna DK; Prathyusha PV; Nagappa M; Bindu PS; Taly AB; Umamaheswara Rao GS; Satishchandra P
Epilepsy Res; 2015 Aug; 114():52-8. PubMed ID: 26088885
[TBL] [Abstract][Full Text] [Related]
4. Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study.
Misra UK; Kalita J; Maurya PK
J Neurol; 2012 Apr; 259(4):645-8. PubMed ID: 21898137
[TBL] [Abstract][Full Text] [Related]
5. Sodium valproate vs phenytoin in status epilepticus: a pilot study.
Misra UK; Kalita J; Patel R
Neurology; 2006 Jul; 67(2):340-2. PubMed ID: 16864836
[TBL] [Abstract][Full Text] [Related]
6. Comparing the efficacy of sodium valproate and levetiracetam following initial lorazepam in elderly patients with generalized convulsive status epilepticus (GCSE): A prospective randomized controlled pilot study.
Nene D; Mundlamuri RC; Satishchandra P; Prathyusha PV; Nagappa M; Bindu PS; Raghavendra K; Saini J; Bharath RD; Thennarasu K; Taly AB; Sinha S
Seizure; 2019 Feb; 65():111-117. PubMed ID: 30682680
[TBL] [Abstract][Full Text] [Related]
7. Levetiracetam versus phenytoin in management of status epilepticus.
Chakravarthi S; Goyal MK; Modi M; Bhalla A; Singh P
J Clin Neurosci; 2015 Jun; 22(6):959-63. PubMed ID: 25899652
[TBL] [Abstract][Full Text] [Related]
8. A Comparison of Intravenous Levetiracetam and Valproate for the Treatment of Refractory Status Epilepticus in Children.
İşgüder R; Güzel O; Ceylan G; Yılmaz Ü; Ağın H
J Child Neurol; 2016 Aug; 31(9):1120-6. PubMed ID: 27080042
[TBL] [Abstract][Full Text] [Related]
9. Tolerability, safety, and side effects of levetiracetam versus phenytoin in intravenous and total prophylactic regimen among craniotomy patients: a prospective randomized study.
Fuller KL; Wang YY; Cook MJ; Murphy MA; D'Souza WJ
Epilepsia; 2013 Jan; 54(1):45-57. PubMed ID: 22738092
[TBL] [Abstract][Full Text] [Related]
10. Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus.
Sathe AG; Mishra U; Ivaturi V; Brundage RC; Cloyd JC; Elm JJ; Chamberlain JM; Silbergleit R; Kapur J; Lowenstein DH; Shinnar S; Cock HR; Fountain NB; Babcock L; Coles LD
J Clin Pharmacol; 2021 Jun; 61(6):763-768. PubMed ID: 33336359
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effect of intravenous levetiracetam in status epilepticus: A meta-analysis and systematic review.
Chu SS; Wang HJ; Zhu LN; Xu D; Wang XP; Liu L
Seizure; 2020 Jan; 74():49-55. PubMed ID: 31830677
[TBL] [Abstract][Full Text] [Related]
12. Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam.
Alvarez V; Januel JM; Burnand B; Rossetti AO
Epilepsia; 2011 Jul; 52(7):1292-6. PubMed ID: 21480881
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of intravenous levetiracetam as an adjunctive treatment in pediatric refractory status epilepticus.
Kim JS; Lee JH; Ryu HW; Lim BC; Hwang H; Chae JH; Choi J; Kim KJ; Hwang YS; Kim H
Pediatr Emerg Care; 2014 Aug; 30(8):525-8. PubMed ID: 25062293
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial.
Chamberlain JM; Kapur J; Shinnar S; Elm J; Holsti M; Babcock L; Rogers A; Barsan W; Cloyd J; Lowenstein D; Bleck TP; Conwit R; Meinzer C; Cock H; Fountain NB; Underwood E; Connor JT; Silbergleit R; ;
Lancet; 2020 Apr; 395(10231):1217-1224. PubMed ID: 32203691
[TBL] [Abstract][Full Text] [Related]
15. Intravenous levetiracetam in clinical practice--Results from an independent registry.
Lang N; Esser W; Evers S; Kellinghaus C; Nguento A; Schlegel U; Gaida B; Gburek-Augustat J; Altenmüller DM; Burghaus L; Hoffmann F; Fiedler B; Bast T; Rehfeld T; Happe S; Seitz RJ; Boor R; Stephani U
Seizure; 2015 Jul; 29():109-13. PubMed ID: 26076852
[TBL] [Abstract][Full Text] [Related]
16. Levetiracetam vs. phenytoin as 2nd-line treatment for status epilepticus: A systematic review and meta-analysis.
DeMott JM; Slocum GW; Gottlieb M; Peksa GD
Epilepsy Behav; 2020 Oct; 111():107286. PubMed ID: 32707535
[TBL] [Abstract][Full Text] [Related]
17. Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors.
Swisher CB; Doreswamy M; Gingrich KJ; Vredenburgh JJ; Kolls BJ
Neurocrit Care; 2012 Feb; 16(1):109-13. PubMed ID: 21882056
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus.
Sánchez Fernández I; Gaínza-Lein M; Lamb N; Loddenkemper T
Neurology; 2019 May; 92(20):e2339-e2348. PubMed ID: 31068480
[TBL] [Abstract][Full Text] [Related]
19. Why we prefer levetiracetam over phenytoin for treatment of status epilepticus.
Zaccara G; Giorgi FS; Amantini A; Giannasi G; Campostrini R; Giovannelli F; Paganini M; Nazerian P;
Acta Neurol Scand; 2018 Jun; 137(6):618-622. PubMed ID: 29624640
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, Safety, and Economics of Intravenous Levetiracetam for Status Epilepticus: A Systematic Review and Meta-Analysis.
Yi ZM; Zhong XL; Wang ML; Zhang Y; Zhai SD
Front Pharmacol; 2020; 11():751. PubMed ID: 32670054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
